tirzepatide surpass 4 for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity Effects of tirzepatide versus insulin

Nagai A, Kim W K, Lee HJ, et al

This dose escalation aims to minimize any discomfort, such as nausea or diarrhea, you might face

Clinical trials have shown that GLP-1 receptor agonists, particularly semaglutide and liraglutide, can reduce liver fat content and improve some markers of liver inflammation

The problem is that weight loss is notoriously difficult to achieve particularly with lifestyle modifications, such as diet and exercise, alone

A 2022 study published in Diabetes, Obesity and Metabolism found that adults over 50 achieved clinically significant weight loss on semaglutide, with cardiovascular and metabolic risk reductions comparable to younger cohorts, though the authors noted the importance of individualized monitoring protocols for older patients given the higher baseline prevalence of comorbidities

Which response is BEST